Potential beneficial impacts of tadalafil on cardiovascular diseases
Open Access
- 10 January 2025
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 88 (4) , 267-272
Abstract
Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor commonly used for the treatment of erectile dysfunction and benign prostatic hyperplasia. Its mechanism of action involves the inhibition of PDE5, leading to increased levels of nitric oxide and cyclic guanosine monophosphate in the corpus cavernosum, which facilitates smooth muscle relaxation. This article reviews studies using tadalafil in the treatment of cardiovascular diseases and emphasizes its potential advantages in conditions such as pulmonary arterial hypertension, atherosclerosis, coronary artery disease, myocardial infarction, heart failure, stroke, diabetic ulcers, and cardiomyopathy. Although tadalafil shows potential efficacy in treating cardiovascular disease, further experimental studies are needed to clarify its pharmacological effects on cardiovascular protection beyond PDE5 inhibition.Keywords
This publication has 55 references indexed in Scilit:
- Is tadalafil associated with decreased risk of major adverse cardiac events or venous thromboembolism in men with lower urinary tract symptoms?World Journal of Urology, 2022
- Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitorsBiomedicine & Pharmacotherapy, 2020
- Heart Failure After Myocardial Infarction: Incidence and PredictorsESC Heart Failure, 2020
- Chronic inhibition of phosphodiesterase 5 with tadalafil affords cardioprotection in a mouse model of metabolic syndrome: role of nitric oxideMolecular and Cellular Biochemistry, 2020
- Tadalafil Prevents Acute Heart Failure with Reduced Ejection Fraction in MiceCardiovascular Drugs and Therapy, 2014
- Stroke after tadalafil useNeurological Sciences, 2013
- Recurrent ischemic stroke associated with sildenafil and tadalafil use in a young adultClinical Neurology and Neurosurgery, 2012
- Heart Failure After Myocardial Infarction: Clinical Implications and TreatmentClinical Cardiology, 2011
- Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic strokeBrain Research, 2006
- Pharmacology and Drug Interaction Effects of the Phosphodiesterase 5 Inhibitors: Focus on α-Blocker InteractionsThe American Journal of Cardiology, 2005